Tirzepatide

Half-life context

Unknown. The current Zepbound label reports approximately 5–6 days; no falsely precise single value is supplied.

Regulatory status

Checked 2026-10-09

FDA product approval

approved product. Zepbound; Mounjaro is a separate labeled product.

Compounding

not established. Compounded products do not carry FDA product approval; legal eligibility is not established here.

Research status

product specific. People meeting labeled weight-management or obstructive-sleep-apnea criteria; other approved products have different indications.

Sport status

unknown. Not individually verified; consult your sport authority.

Evidence A

Established human clinical or approved-product evidence for the specified indication.

Grades describe the cited population and indication, not safety or suitability for an individual.

Population: People meeting labeled weight-management or obstructive-sleep-apnea criteria; other approved products have different indications.

Indication: Approved labeled indication only.

Basis: Product-label clinical evidence.

Risks

• Gastrointestinal reactions, pancreatitis and dehydration-related kidney injury are among label warnings.

Contraindications

• Personal or family medullary thyroid carcinoma, MEN2, or serious hypersensitivity: see the full product label.

Interactions

• Insulin and sulfonylureas can increase hypoglycemia risk; delayed gastric emptying can affect oral medicines.
• The label warns of reduced oral hormonal contraceptive efficacy; discuss alternative or additional contraception with the prescribing clinician.

What to record

• Existing clinician-directed records, symptoms and dated health measurements.
• Record missing data; trends do not demonstrate causation.

A licensed clinician must interpret the evidence for your situation. This entry provides education, not treatment instructions.

Review: source-curated; clinician review pending

Sources

• Approved product label. Checked 2026-10-09